Theory Paper IDrNB Cardiology – Theory Notes

LEFT VENTRICULAR NON-COMPACTION (LVNC)

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IDEFINITION, NOMENCLATURE SHIFT AND PATHOPHYSIOLOGY (ESC 2023 CARDIOMYOPATHY GUIDELINES)

  • Traditional Definition vs. 2023 ESC Paradigm Shift (“Excessive Trabeculation”): Historically termed Left Ventricular Non-Compaction (LVNC) and attributed to an arrest of embryological myocardial compaction between weeks 5 and 8 of gestation, the 2023 ESC Guidelines for the Management of Cardiomyopathies officially recommend replacing the term “LVNC” with “Hypertrabeculation” or “Excessive Trabeculation”. Modern developmental biology demonstrates that compact and trabecular layers grow via differential proliferation rather than simple “compaction” of pre-existing trabeculae, and excessive trabeculation in adults is most commonly either a phenotypic trait accompanying an underlying Dilated (DCM), Nondilated LV (NDLVC), or Hypertrophic (HCM) Cardiomyopathy, or a reversible physiological adaptation to chronic preload/afterload increase (pregnancy, vigorous athletic training, sickle cell/chronic anemia).
  • Morphological Characteristics: Bi-layered myocardial appearance consisting of a thin compacted (C) epicardial layer and a thick non-compacted (NC) endocardial layer composed of prominent muscular trabeculations and deep intertrabecular recesses that communicate directly with the left ventricular cavity (and have no communication with the epicardial coronary circulation), predominantly affecting the LV apex, mid-lateral, and mid-inferior walls.
  • Genetic Architecture: Highly heterogeneous; sarcomeric gene variants—most commonly MYH7 (most frequent in isolated excessive trabeculation), MYBPC3, TTN (Titin), and ACTC1—account for the majority of familial cases. Crucially, arrhythmogenic high-risk genotypes—including LMNA, SCN5A, RBM20, FLNC, and DES—must be identified because they carry a high risk of malignant arrhythmias and conduction block independent of trabeculation extent, while X-linked TAFAZZIN (TAZ) mutations cause pediatric Barth Syndrome (LV hypertrabeculation/DCM + neutropenia + skeletal myopathy + 3-methylglutaconic aciduria) and MIB1 / NOTCH pathway variants link hypertrabeculation with congenital heart defects (Ebstein anomaly, BAV, VSD).

IICLINICAL PRESENTATION AND THE CLASSIC TRIAD

  • Spectrum of Presentation: Ranges from completely asymptomatic individuals detected incidentally on imaging or family screening to severe neonatal/adult cardiomyopathy.
  • Classic Clinical Complication Triad:
    • Heart Failure (Systolic and Diastolic Dysfunction): Progressive HFrEF (from subendocardial hypoperfusion and sarcomeric dysfunction) and diastolic dysfunction (abnormal relaxation and restriction caused by extensive spongy trabecular mass).
    • Atrial and Ventricular Arrhythmias / Sudden Cardiac Death (SCD): Atrial Fibrillation (10 to 25 percent), bundle branch blocks, WPW pre-excitation (especially in pediatric/Ebstein overlap), and Ventricular Tachycardia (VT) / SCD.
    • Systemic Thromboembolism: Sluggish swirling blood flow within deep intertrabecular recesses (especially when accompanied by LV systolic dysfunction or Atrial Fibrillation) predisposes to LV mural/recess thrombi, ischemic stroke, transient ischemic attack, or systemic mesenteric/renal embolism.

IIIMULTIMODALITY DIAGNOSTIC CRITERIA

  • Diagnostic Caveat: Because isolated imaging ratios have a high false-positive rate in healthy populations, diagnosis requires combining morphological cut-offs with clinical phenotype (LVEF, family history, genetics, or CMR fibrosis).

ATransthoracic Echocardiography Criteria (Contrast Echo Enhances Recess Visualization)

  • Jenni Criteria (2001 — Most Widely Used Echo Standard): Measured in the parasternal short-axis view at end-systole: (1) Bilayered myocardium with a Non-Compacted to Compacted (NC/C) ratio greater than 2.0 at end-systole; (2) Predominant localization in the mid-lateral, apical, and mid-inferior segments; (3) Color Doppler evidence of deep perfused intertrabecular recesses communicating with the LV cavity; and (4) Absence of coexisting cardiac structural abnormalities.
  • Chin Criteria (1990): Ratio of the distance from the epicardial surface to the trough of the trabecular recess (X) divided by the distance from the epicardial surface to the peak of the trabeculation (Y) of 0.5 or less at end-diastole at the LV apex.
  • Stöllberger Criteria (2002): More than three prominent trabeculations protruding from the LV wall apical to the papillary muscles, visible in a single image plane at end-diastole, with intertrabecular spaces perfused from the ventricular cavity on color Doppler.

BCardiac Magnetic Resonance (CMR) Criteria (Reference Standard for Tissue Characterization)

  • Petersen Criteria (2005): Measured on long-axis cine views (excluding the true apical cap, segment 17) at end-diastole: Non-Compacted to Compacted (NC/C) thickness ratio greater than 2.3 at end-diastole.
  • Jacquier Volumetric Criteria (2010): Trabeculated LV myocardial mass greater than 20 percent of the global LV mass at end-diastole (more reproducible than single-point linear thickness ratios).
Diagnostic Criterion Modality & Cardiac Phase Quantitative Cut-off Key Clinical Feature / Limitation
Jenni Criteria (2001) 2D Echo (Short-Axis) at End-Systole NC / C ratio > 2.0 Requires Color Doppler flow in deep recesses from LV cavity; most specific echo rule
Chin Criteria (1990) 2D Echo at End-Diastole X / Y ratio <= 0.5 Trough-to-epicardium (X) vs. peak-to-epicardium (Y) at apex
Petersen Criteria (2005) Cardiac MRI (Long-Axis) at End-Diastole NC / C ratio > 2.3 High sensitivity; high false-positive rate (43% of MESA participants had at least one segment above 2.3)
Jacquier Criteria (2010) Cardiac MRI (Short-Axis Stack) at End-Diastole Trabeculated LV mass > 20% of total LV mass Volumetric quantification of global trabecular burden

IVMANAGEMENT STRATEGIES (ESC 2023 CARDIOMYOPATHY / HRS 2019 GUIDELINES)

  • Phenotype-Directed Heart Failure Therapy: Management follows standard DCM / HFrEF Guideline-Directed Medical Therapy (GDMT) when systolic dysfunction is present—combining ARNI (Sacubitril/Valsartan) or ACEi/ARB, Beta-Blockers, MRAs, and SGLT2 Inhibitors, plus Cardiac Resynchronization Therapy (CRT) when LVEF is 35 percent or less with LBBB. Asymptomatic individuals with isolated hypertrabeculation, normal LVEF, no LGE on CMR, and negative family/genetic history require reassurance and do not require medical therapy or sports restriction.
  • Arrhythmia and Sudden Cardiac Death (SCD) Prevention:
    • Secondary Prevention (Class I): ICD implantation is recommended in survivors of cardiac arrest or sustained VT with hemodynamic compromise.
    • Primary Prevention: Guided by the underlying cardiomyopathy phenotype (LVEF 35 percent or less despite 3 months of optimal GDMT), presence of extensive Late Gadolinium Enhancement (LGE) on CMR, unexplained syncope, or high-risk pathogenic variants (LMNA, FLNC, PLN, DSP, RBM20, SCN5A) (where genotype-specific risk calculators guide early ICD placement even with LVEF greater than 35 percent).
    • Thromboembolism Prophylaxis (Oral Anticoagulation — Warfarin or DOACs):
    • Class I Indications: Mandatory in patients with excessive trabeculation/LVNC who have Atrial Fibrillation, a prior thromboembolic event (stroke/TIA/systemic embolism), or a documented intracavitary/intertrabecular LV thrombus (evaluated via contrast echocardiography or early/late gadolinium CMR).
    • Class IIb Consideration: May be considered in patients with severe LV systolic dysfunction (LVEF less than 30 to 35 percent) in sinus rhythm when accompanied by extensive deep recesses or hypercoagulable states, though routine anticoagulation for isolated hypertrabeculation with normal LVEF and sinus rhythm is not indicated.

VLANDMARK EVIDENCE: PROGNOSIS IS DRIVEN BY LVEF AND LGE, NOT TRABECULATION ALONE

  • MESA Study (Zemrak et al., JACC 2014): In 2,742 asymptomatic Multi-Ethnic Study of Atherosclerosis participants without baseline heart disease, 43 percent met Petersen CMR criteria (NC/C greater than 2.3) in at least one myocardial segment, yet trabeculation extent was not associated with deterioration in LV volumes or LVEF over 9.5 years of follow-up—proving that isolated hypertrabeculation in healthy individuals is a benign anatomical variant.
  • Multicenter CMR Outcome Meta-Analyses (Andreini et al., JACC 2016; Grigoratos et al., JACC Cardiovasc Imaging 2019): Demonstrated that in patients fulfilling imaging criteria for LVNC, the extent of non-compacted myocardium (NC/C ratio or trabeculated mass) does NOT independently predict mortality or MACE; instead, adverse prognosis is dictated entirely by reduced LVEF and the presence of myocardial fibrosis (LGE on CMR).Patients with preserved LVEF (50 percent or greater) and no LGE on CMR have an event rate virtually identical to the general population.

VIPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • Avoiding Over-Diagnosis in Physiological High-Preload States: In India, chronic severe iron-deficiency or hemolytic anemia, pregnancy, and athletic training frequently induce reversible left ventricular hypertrabeculation meeting Petersen or Jenni cut-offs. Labeling such individuals with “LVNC cardiomyopathy” causes unnecessary anxiety and inappropriate anticoagulation; normal LVEF, normal GLS, and absence of LGE on CMR confirm a benign adaptive phenotype.
  • Contrast Echocardiography in Resource-Limited Settings: When CMR is unavailable, administering an intravenous Ultrasound Enhancing Agent (echo contrast) (or agitated saline/blood contrast where commercial microbubbles are costly) is essential both to clearly delineate the endocardial border of deep apical recesses and to exclude apical intertrabecular thrombi vs. Apical Hypertrophic Cardiomyopathy or Left Ventricular Endomyocardial Fibrosis (LV-EMF).
  • Family Cascade Screening and Pediatric Syndromes: When true cardiomyopathy with hypertrabeculation is diagnosed, clinical and echocardiographic screening of first-degree relatives (Class I) and targeted Next-Generation Sequencing (NGS) panels (including sarcomeric genes, high-risk arrhythmic genes, and TAFAZZIN in male infants with neutropenia/aciduria) are recommended.

Key references

  • Arbelo E, Protonotarios A, Gimeno JR, et al.: 2023 ESC Guidelines for the management of cardiomyopathies, European Heart Journal, 2023.
  • Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA: Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy, Heart, 2001.
  • Petersen SE, Selvanayagam JB, Wiesmann F, et al.: Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging, Journal of the American College of Cardiology, 2005.
  • Zemrak F, Ahlman MA, Captur G, et al. (MESA Investigators): The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study, Journal of the American College of Cardiology, 2014.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.